Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Fibrosis inhibition and muscle histopathology improvement in laminin-alpha2-deficient mice.

Nevo Y, Halevy O, Genin O, Moshe I, Turgeman T, Harel M, Biton E, Reif S, Pines M.

Muscle Nerve. 2010 Aug;42(2):218-29. doi: 10.1002/mus.21706.

PMID:
20589893
2.

Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone.

Turgeman T, Hagai Y, Huebner K, Jassal DS, Anderson JE, Genin O, Nagler A, Halevy O, Pines M.

Neuromuscul Disord. 2008 Nov;18(11):857-68. doi: 10.1016/j.nmd.2008.06.386. Epub 2008 Jul 30.

PMID:
18672370
3.

Functional resolution of fibrosis in mdx mouse dystrophic heart and skeletal muscle by halofuginone.

Huebner KD, Jassal DS, Halevy O, Pines M, Anderson JE.

Am J Physiol Heart Circ Physiol. 2008 Apr;294(4):H1550-61. doi: 10.1152/ajpheart.01253.2007. Epub 2008 Feb 8.

4.

Inhibition of muscle fibrosis and improvement of muscle histopathology in dysferlin knock-out mice treated with halofuginone.

Halevy O, Genin O, Barzilai-Tutsch H, Pima Y, Levi O, Moshe I, Pines M.

Histol Histopathol. 2013 Feb;28(2):211-26. doi: 10.14670/HH-28.211.

PMID:
23275304
5.

Focusing on fibrosis: halofuginone-induced functional improvement in the mdx mouse model of Duchenne muscular dystrophy.

McLoon LK.

Am J Physiol Heart Circ Physiol. 2008 Apr;294(4):H1505-7. doi: 10.1152/ajpheart.00176.2008. Epub 2008 Feb 29. No abstract available.

6.

Improved muscle strength and mobility in the dy(2J)/dy(2J) mouse with merosin deficient congenital muscular dystrophy treated with Glatiramer acetate.

Dadush O, Aga-Mizrachi S, Ettinger K, Tabakman R, Elbaz M, Fellig Y, Yanay N, Nevo Y.

Neuromuscul Disord. 2010 Apr;20(4):267-72. doi: 10.1016/j.nmd.2010.02.002. Epub 2010 Mar 20.

PMID:
20304648
7.

Halofuginone and muscular dystrophy.

Pines M, Halevy O.

Histol Histopathol. 2011 Jan;26(1):135-46. doi: 10.14670/HH-26.135. Review.

PMID:
21117034
8.

Reduction in dermal fibrosis in the tight-skin (Tsk) mouse after local application of halofuginone.

Pines M, Domb A, Ohana M, Inbar J, Genina O, Alexiev R, Nagler A.

Biochem Pharmacol. 2001 Nov 1;62(9):1221-7.

PMID:
11705455
9.

Halofuginone inhibits Smad3 phosphorylation via the PI3K/Akt and MAPK/ERK pathways in muscle cells: effect on myotube fusion.

Roffe S, Hagai Y, Pines M, Halevy O.

Exp Cell Res. 2010 Apr 1;316(6):1061-9. doi: 10.1016/j.yexcr.2010.01.003. Epub 2010 Jan 11.

PMID:
20060825
10.

Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention.

Zion O, Genin O, Kawada N, Yoshizato K, Roffe S, Nagler A, Iovanna JL, Halevy O, Pines M.

Pancreas. 2009 May;38(4):427-35. doi: 10.1097/MPA.0b013e3181967670.

PMID:
19188864
11.

Halofuginone improves muscle-cell survival in muscular dystrophies.

Bodanovsky A, Guttman N, Barzilai-Tutsch H, Genin O, Levy O, Pines M, Halevy O.

Biochim Biophys Acta. 2014 Jul;1843(7):1339-47. doi: 10.1016/j.bbamcr.2014.03.025. Epub 2014 Apr 2.

12.

Losartan, a therapeutic candidate in congenital muscular dystrophy: studies in the dy(2J) /dy(2J) mouse.

Elbaz M, Yanay N, Aga-Mizrachi S, Brunschwig Z, Kassis I, Ettinger K, Barak V, Nevo Y.

Ann Neurol. 2012 May;71(5):699-708. doi: 10.1002/ana.22694.

PMID:
22522482
13.

Laminin alpha1 chain improves laminin alpha2 chain deficient peripheral neuropathy.

Gawlik KI, Li JY, Petersén A, Durbeej M.

Hum Mol Genet. 2006 Sep 15;15(18):2690-700. Epub 2006 Aug 7.

PMID:
16893907
14.

Secondary reduction of alpha7B integrin in laminin alpha2 deficient congenital muscular dystrophy supports an additional transmembrane link in skeletal muscle.

Cohn RD, Mayer U, Saher G, Herrmann R, van der Flier A, Sonnenberg A, Sorokin L, Voit T.

J Neurol Sci. 1999 Mar 1;163(2):140-52.

PMID:
10371075
15.

Halofuginone: a novel antifibrotic therapy.

Pines M, Nagler A.

Gen Pharmacol. 1998 Apr;30(4):445-50. Review.

PMID:
9522159
16.

Omigapil treatment decreases fibrosis and improves respiratory rate in dy(2J) mouse model of congenital muscular dystrophy.

Yu Q, Sali A, Van der Meulen J, Creeden BK, Gordish-Dressman H, Rutkowski A, Rayavarapu S, Uaesoontrachoon K, Huynh T, Nagaraju K, Spurney CF.

PLoS One. 2013 Jun 6;8(6):e65468. doi: 10.1371/journal.pone.0065468. Print 2013.

17.

Expression of laminin alpha1, alpha2, alpha4, and alpha5 chains, fibronectin, and tenascin-C in skeletal muscle of dystrophic 129ReJ dy/dy mice.

Ringelmann B, Röder C, Hallmann R, Maley M, Davies M, Grounds M, Sorokin L.

Exp Cell Res. 1999 Jan 10;246(1):165-82.

PMID:
9882526
18.

Electrotransfer of naked DNA in the skeletal muscles of animal models of muscular dystrophies.

Vilquin JT, Kennel PF, Paturneau-Jouas M, Chapdelaine P, Boissel N, Delaère P, Tremblay JP, Scherman D, Fiszman MY, Schwartz K.

Gene Ther. 2001 Jul;8(14):1097-107.

19.

Halofuginone promotes satellite cell activation and survival in muscular dystrophies.

Barzilai-Tutsch H, Bodanovsky A, Maimon H, Pines M, Halevy O.

Biochim Biophys Acta. 2016 Jan;1862(1):1-11. doi: 10.1016/j.bbadis.2015.10.007. Epub 2015 Oct 8.

20.

Myoblast transplantations lead to the expression of the laminin alpha 2 chain in normal and dystrophic (dy/dy) mouse muscles.

Vilquin JT, Guérette B, Puymirat J, Yaffe D, Tomé FM, Fardeau M, Fiszman M, Schwartz K, Tremblay JP.

Gene Ther. 1999 May;6(5):792-800.

Supplemental Content

Support Center